EKF Diagnostics Holdings plc
("EKF Diagnostics" or the "Company")
Confirmation of share cancellation
Total voting rights
EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed medical diagnostics business, refers to its announcement dated 3 October 2017 and confirms that the 6,630,032 referred to in that announcement, being the majority of the shares held in the escrow account together with the 1,000,000 shares bought back and currently held in treasury, will be cancelled with effect from 3 November 2017 (the "Cancellation").
Following the Cancellation, the Company's total issued share capital will consist of 458,632,749 ordinary shares of 1 pence each ("Ordinary Shares") with one voting right per share. The Company will not hold any Ordinary Shares in treasury.
Therefore, the total number of voting rights in the Company will be 457,632,749.
The above figure of 457,632,749 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.
For further information please contact:
EKF Diagnostics Holdings plc |
www.ekfdiagnostics.com |
Christopher Mills, Non-Executive Chairman |
Tel: 029 2071 0570 |
Julian Baines, CEO |
|
Richard Evans, FD & COO |
|
|
|
|
|
N+1 Singer (Nomad & Broker) |
Tel: 020 7496 3000 |
Alex Price / Shaun Dobson |
|
|
|
|
|
Walbrook PR Limited |
Tel: 020 7933 8780 or [email protected] |
Paul McManus / Lianne Cawthorne |
Mob: 07980 541 893 / 07584 391 303 |
